Media headlines about Urogen Pharma (NASDAQ:URGN) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Urogen Pharma earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.0719309828008 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
A number of equities analysts recently commented on the company. Oppenheimer reiterated a “buy” rating on shares of Urogen Pharma in a research report on Thursday, March 22nd. Jefferies Group reiterated a “buy” rating on shares of Urogen Pharma in a research report on Monday, March 19th. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $65.00 price objective on shares of Urogen Pharma in a research report on Friday, March 16th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $43.33.
Shares of Urogen Pharma stock opened at $49.69 on Monday. Urogen Pharma has a one year low of $13.01 and a one year high of $58.66. The company has a market cap of $683.31 and a P/E ratio of -23.22.
About Urogen Pharma
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.